头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢阻肺急性加重期临床疗效.docVIP

头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢阻肺急性加重期临床疗效 　　[摘要] 目的 探?头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢阻肺急性加重期的临床效果。 方法 收集2015年1月～2016年5月我院收治的106例慢阻肺急性加重期患者，随机分为研究组和对照组，每组53例患者，两组患者均予常规治疗，在常规治疗基础上，对照组使用头孢哌酮钠舒巴坦钠治疗，研究组使用头孢哌酮钠舒巴坦钠联合喹诺酮治疗，治疗1周后，对比两组的临床疗效、治疗前后动脉血氧分压（PaO2）、动脉血二氧化碳分压（PaCO2）、不良反应情况。 结果 研究组的总有效率（92.45%）与对照组的75.47%比较更高，差异有统计学意义（P0.05）。 结论 头孢哌酮钠舒巴坦钠联合喹诺酮治疗慢阻肺急性加重期效果确切，可有效缓解患者的临床症状，改善血气指标，安全性高，可在临床推广应用 [关键词] 慢阻肺；急性加重期；头孢哌酮钠舒巴坦钠；喹诺酮 [中图分类号] R917 [文献标识码] B [文章编号] 1673-9701（2017）09-0121-03 Clinical effect of cefoperazone sodium and sulbactam sodium combined with quinolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease LIU Yibing Department of Respiratory， Xinmin People’s Hospital in Liaoning Province， Xinmin 110300， China [Abstract] Objective To investigate the clinical effect of cefoperazone sodium and sulbactam sodium combined with quinolone in the treatment of acute exacerbation of chronic obstructive pulmonary disease（COPD）. Methods A total of 106 patients with acute exacerbation of chronic obstructive pulmonary disease in our hospital from January 2015 to May 2016 were enrolled and randomly divided into study group and control group， 53 cases in each group. Both groups were treated with routine therapy. On the basis of the routine treatment， the control group was treated with cefoperazone sodium and sulbactam sodium， while the treatment group was treated with cefoperazone sodium and sulbactam sodium combined with quinolone. After 1 week of treatment， the clinical efficacy， the arterial oxygen pressure（PaO2）， the arterial carbon dioxide partial pressure（PaCO2） before and after treatment and adverse reactions between two groups were compared. Results The total effective rate was 92.45% in the study group， higher than that in the control group（75.47%）， and the difference was statistically significant（P0.05）. Conclusion Cefoperazone sodium and sulbactam sodium combined with quinolone in the treatment of acute exacerbation of chronic obstructive pulmonary di